Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Immunotherapy × olaparib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 83 Breast Neoplasms 60 Prostatic Neoplasms 30 Triple Negative Breast Neoplasms 26 Neoplasms 24 Fallopian Tube Neoplasms 22 Neoplasm Metastasis 18 Pancreatic Neoplasms 17 Endometrial Neoplasms 17 Small Cell Lung Carcinoma 13 Carcinoma, Ovarian Epithelial 10 Sarcoma 9 Carcinoma, Non-Small-Cell Lung 9 Stomach Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 8 Recurrence 8 Lung Neoplasms 7 Glioma 7 Fanconi Anemia, Complementation Group D1 7 Parkinson Disease 4, Autosomal Dominant Lewy Body 6 Glioblastoma 6 Colorectal Neoplasms 6 Lymphoma, Non-Hodgkin 5 Cholangiocarcinoma 5 Urinary Bladder Neoplasms 4 Solid Tumors 4 Neuroendocrine Tumors 4 Metastatic Castration-resistant Prostate Cancer 4 Carcinoma, Squamous Cell 4 Advanced Solid Tumors 4

Interventions

tislelizumab 2 Oxaliplatin 2 tremelimumab 1 olaparib 1 durvalumab 1 apatinib 1 Tegafur 1 Immunotherapy, Adoptive 1 Dacarbazine 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04169841 2024-02-13

GUIDE2REPAIR

Centre Georges Francois Leclerc

Phase 2 Active not recruiting

Immunotherapy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡